Search

A patent application titled "Oncologic Variations Associated With Cancer And Methods Of Treatment" was published online by inventors Tina Garyantes, Patrick Mooney, and Christopher Natale. The application focuses on detecting oncogenic variations in genomic DNA related to cancer and identifying cancers treatable with LNS8801. The method involves analyzing samples for oncologic variations, determining treatment eligibility with LNS8801, and administering the treatment. The application highlights the importance of identifying mutations in cancers to guide treatment decisions and develop new therapeutics. [Extracted from the article]

A patent application titled "High-Voltage Pulse Generator With Discharge Circuit" was published online by inventors Athos, Brian G.; Uecker, Darrin R.; Xiao, Shu. The application relates to generating nanosecond pulsed electric fields (nsPEF) for electrotherapy to treat cancerous tumors. The invention aims to provide better control over pulse generator charge state for safe and effective cancer studies and treatments in human subjects. The patent application emphasizes the potential benefits of using nsPEFs to trigger apoptosis in cancerous tumors while minimizing harm to normal cells. [Extracted from the article]

A patent application titled "Pharmaceutical Combinations Comprising A Tead Inhibitor And Uses Thereof For The Treatment Of Cancers" was published online on November 14, 2024, by inventors from France and Switzerland. The application focuses on novel combination therapies involving a TEAD inhibitor and other therapeutically active agents to synergistically inhibit proliferation and induce apoptosis in cancers. The inventors aim to address the complexity of tumors and drug resistance mechanisms to improve cancer treatment efficacy. The patent application outlines various aspects of the invention, including methods of treatment and specific combinations of therapeutically active agents. [Extracted from the article]

Researchers have submitted a patent application for "Anti-Latent Tgf-Beta 1 Antibodies And Methods Of Use" to the USPTO. The patent application focuses on the development of antibodies that inhibit the activation of latent TGF-beta 1, which plays a role in various cellular processes and disease states, including cancer and fibrosis. The inventors have created cross-species, humanized, and optimized antibodies that target latent TGF-beta 1, potentially offering new treatment options for fibrosis and cancer. [Extracted from the article]

A patent application titled "Integrated Microfluidic System For Monitoring A Sample Over A Digestion Process" was published online by inventors from various locations in California. The application focuses on the need for improved tissue dissociation methods to enhance single-cell analysis for tissue diagnostics and disease understanding, particularly in cancer research. The system described in the patent application involves a microfluidic device for processing tissue samples, incorporating a camera for monitoring the tissue sample during the digestion and disaggregation process. This innovative technology aims to address the challenges of tissue processing and monitoring, potentially advancing personalized medicine and therapy development. [Extracted from the article]

The patent application titled "Quinoline Compounds As Inhibitors Of Kras" discusses the role of Ras proteins in cancer development, particularly focusing on KRAS mutations in pancreatic, colorectal, and lung cancers. The inventors propose compounds and pharmaceutical compositions to inhibit KRAS activity, potentially offering new treatment options for diseases characterized by KRAS mutations. This research highlights the importance of targeting mutant KRAS in clinical treatments for various types of cancer. [Extracted from the article]

A patent application for "2-Azabicyclo[2.2.1]heptane Kras Inhibitors" by inventors from various locations was made available online on November 7, 2024. The application focuses on the development of compounds and pharmaceutical compositions to inhibit KRAS activity, which plays a critical role in human cancers, particularly in pancreatic, colorectal, and lung cancers. The patent application aims to provide methods for treating diseases characterized by KRAS mutations, offering potential therapeutic options for patients with such conditions. [Extracted from the article]

A patent application titled "Il15/Il15r Alpha Heterodimeric Fc-Fusion Proteins For The Treatment Of Blood Cancers" was published online, detailing methods for treating blood cancers such as multiple myeloma. The application describes the use of heterodimeric proteins to induce the proliferation of immune cells and production of specific proteins in subjects with blood cancers. Despite advancements in treatment options, relapsed/refractory multiple myeloma remains a significant unmet medical need. The patent application provides detailed information on the composition and administration of these proteins for potential therapeutic use. [Extracted from the article]

A patent application titled "Illuminating Tissue Samples In Wide Field Fluorescence Lifetime Imaging Microscopy" was published online on November 7, 2024, by inventors Olender, Derek S.; Wang, Lu; and Wellner MD, Rachel Beth. The application addresses the need for improved methods of diagnosing cancer through tissue biopsies by evenly illuminating tissue samples using Fluorescence Lifetime Imaging Microscopy (FLIM). The technology aims to enhance the accuracy and efficiency of cancer diagnosis by providing a more comprehensive and detailed analysis of tissue samples, potentially improving patient outcomes and reducing delays in treatment initiation. [Extracted from the article]

The patent application titled "Genetically Modified Major Histocompatibility Complex Mice" discusses the development of non-human animals, specifically rodents, with humanized MHC II proteins to mimic aspects of the human immune system. These genetically modified animals express functional MHC II complexes on their cell surfaces, providing a platform for studying immune responses and identifying peptides associated with human MHC class II proteins. The application highlights the importance of these biological systems in advancing research on diseases like cancer and autoimmune disorders. [Extracted from the article]

A patent application titled "Digital Counting Of Individual Molecules By Stochastic Attachment Of Diverse Labels" was published online on November 7, 2024, by inventors Fodor and Fu. The application focuses on high-sensitivity single molecule digital counting through stochastic labeling, providing a method for determining the absolute number of molecules in a sample. This innovative technique has potential applications in genetics, risk assessment, and disease prevention, offering a more accurate and efficient method for identifying genetic variations and expression patterns. [Extracted from the article]

A patent application titled "Molecules For Modulating The Immune System And Uses Thereof" was submitted by a group of inventors on April 26, 2024, and made available online on November 7, 2024. The application focuses on developing molecules to regulate cell-mediated immunity and activate the body's immune response to target cancer cells. The inventors propose various methods and compositions for treating autoimmune disorders, cancer, and modulating immune cell activity. The patent application emphasizes the need for treatments that can effectively regulate cell-mediated immunity and activate immune responses against cancer cells. [Extracted from the article]

Researchers have submitted a patent application for methods of detecting cancer using markers from macrophages and neutrophils, as well as non-phagocytic cells. The application aims to provide personalized diagnostic methods for early cancer detection and monitoring. By measuring specific markers in different cell populations, the methods can aid in diagnosing cancer, assessing the risk of developing cancer, prognosing cancer, monitoring cancer progression or regression, and evaluating the efficacy of cancer treatments. [Extracted from the article]

The patent application titled "Methylation Sequencing Methods And Compositions" by inventors from various locations introduces a method to identify methylated cytosine nucleotides in a target sequence without disrupting the nucleotide sequence. The method involves creating compositions with methylated cytosine bases and utilizing extension reactions to generate nucleic acid molecules for sequencing. This innovative approach aims to provide insights into genetic profiles related to cancer and patient responsiveness to therapies. For more detailed information, readers can refer to the full patent application. [Extracted from the article]

A patent application titled "Systems And Methods For Conforming Treatment Applicators To Non-Uniform Surfaces" was published online on November 7, 2024, by inventor Anna O. LIKHACHEVA. The application focuses on improving radiotherapy systems for skin cancer treatment, specifically addressing the challenges of delivering therapy to non-uniform skin surfaces. The invention involves an applicator guide with catheters that can conform to a patient's skin, allowing for precise delivery of therapy. This innovation aims to enhance the effectiveness and comfort of treatments for skin cancer and other skin-based diseases. [Extracted from the article]

A patent application titled "Handlebar Extension Apparatus And Associated Bicycle Exercise Arrangement" was published online by inventors Gregory and Johnson. The invention aims to address cyclist comfort and stability on indoor bike trainers, particularly for those using road or racing bicycles with drop handlebars. The apparatus includes a strut arrangement and brace to provide stationary stability and adjustable angles for desired rider ergonomics. This innovation seeks to enhance the comfort and safety of cyclists during indoor training sessions. [Extracted from the article]

A patent application by inventors from Daegu, South Korea, describes a target material separation control device using a laser diode for accurate and smooth opening and closing of a valve in a disk-type device that separates target cells like circulating tumor cells from blood samples. The device aims to improve the performance of cell separation and control devices for early cancer diagnosis and monitoring. The invention utilizes laser technology to increase the wax temperature of the valve, enabling precise separation of target cells. The patent application highlights the potential of this technology for non-invasive prenatal testing and early cancer detection. [Extracted from the article]

A patent application titled "Cyclic Urea Kras Inhibitors" was published online on October 31, 2024, by inventors from various locations in the United States. The application focuses on the development of compounds and pharmaceutical compositions to inhibit KRAS activity, particularly targeting mutant KRAS, which plays a critical role in various human cancers. The patent application outlines methods for inhibiting KRAS activity, manufacturing medicaments for therapy, and treating diseases or disorders associated with KRAS mutations. The research aims to provide potential clinical treatments for diseases characterized by KRAS involvement, such as pancreatic, colorectal, and lung cancers. [Extracted from the article]

A patent application by inventor Stanley Kim discusses a method and composition for treating sensory issues related to sexual function, specifically focusing on anogenital sensory disorders. The formulation includes pirenzepine and aims to address disruptions in sensation that can impact sexual arousal, orgasm, and overall sexual satisfaction. The application highlights the importance of improving sensitivity in individuals experiencing hyposensitivity, hypersensitivity, or pain in the anogenital region, with a particular focus on addressing sexual sensory disorders in both men and women. [Extracted from the article]

A patent application titled "Antibody Molecules And Conjugates" was published online on October 31, 2024, by inventors from various locations. The application focuses on developing bispecific antibody molecules capable of targeting both EGFR and c-Met, which are involved in cancer resistance mechanisms. These antibody molecules aim to improve treatment efficacy by selectively delivering drugs to tumors expressing both targets while minimizing toxicity in normal tissues. The patent application outlines specific antibody structures and conjugates for potential cancer treatment applications. [Extracted from the article]

A patent application titled "Cancer Classification With Cancer Signal Of Origin Thresholding" was published online on October 31, 2024, by inventors from various locations in the United States. The application focuses on analyzing methylation sequencing data from cell-free DNA to detect, diagnose, and monitor diseases like cancer. The method involves training and deploying a cancer classifier to predict the likelihood of cancer presence in a test sample based on specific features identified through sequencing data analysis. The patent application emphasizes the importance of early disease detection for timely treatment and improved survival rates. [Extracted from the article]

A patent application titled "Systems And Method For Monitoring Penile Blood Flow During Surgery" was published online on October 31, 2024, by inventors from various locations in the United States. The patent application focuses on an optical penile structure function monitoring system that aims to detect penile blood flow and tumescence and flaccid penile events during surgery. The system includes a measuring probe and a control system, with various alternative embodiments and claims outlined in the document. This patent application addresses issues related to prostate cancer surgery, erectile dysfunction, and male urologic surgical procedures, providing potential solutions for monitoring penile function during medical procedures. [Extracted from the article]

A patent application titled "Method And System For Selecting A Clinical Pathway" was published online by inventors CARBAJO, Richard Simon; KILLEEN, Ronan; O'GORMAN, Mitchell. The application focuses on a clinical decision support system that aims to improve diagnostic accuracy and reduce errors in medical imaging. The system utilizes data analysis to infer specific health conditions and guide practitioners in selecting appropriate diagnostic tests, potentially minimizing unnecessary procedures and patient harm. The patent application highlights the importance of informed decision-making in medical diagnostics and emphasizes the potential benefits of computer-based diagnostic support tools. [Extracted from the article]

A patent application by inventors from Kyoto, Japan, for a "Flow Channel Chip And Separation System" has been made available online. The system aims to stabilize the separation of specific types of dielectric particles from a suspension using a flow channel chip with separation and sensor electrodes. This innovative system offers advantages in the field of biology for research and development involving property analysis, separation, and concentration of cells and microorganisms. The patent application details the technical aspects and advantages of the invention, providing a novel approach to particle separation in microfluidic devices. [Extracted from the article]

A patent application by inventors Yang and Zhou introduces techniques using deep neural networks for outcome predictions in disease progression, particularly in cancer cases. The method involves analyzing microscopy images, generating outcome predictions with a trained deep neural network, and aggregating these predictions to provide an overall outcome prediction. The application aims to improve accuracy in predicting disease progression, potentially benefiting patients by guiding treatment decisions. The patent application emphasizes the use of advanced technology to enhance healthcare practices and outcomes. [Extracted from the article]

The patent application titled "Calibrating Radiological Data Based On Cell Distribution" discusses methods for analyzing radiological and microscopy images to determine biological parameters, such as metabolic activity, in tissues, particularly cancer cells. The application highlights the importance of accurately calibrating radiological data to account for cell distribution within tissues, which can impact the interpretation of metabolic activity in tumors. By correcting raw values based on cell distribution, the calibrated values provide a more accurate representation of the biological parameters of interest, aiding in diagnosis, staging, and treatment planning for various cancers. [Extracted from the article]

The patent application titled "Calibration Method, Calibration Device And Calibration System Of Laser Positioning System" aims to address the issue of inconsistency in radiation therapy caused by the misalignment of laser positioning systems in different chambers. The inventors propose a method involving a calibration device with a calibration die to ensure accurate positioning of patients for treatment. By comparing positioning marks formed by laser emitters in different chambers, adjustments can be made to maintain the correct treatment position. This innovation seeks to enhance the effectiveness and precision of radiation therapy systems, particularly in targeting tumor cells while minimizing damage to surrounding tissues. [Extracted from the article]

A patent application by inventor Eric Cosatto introduces a method and system for diagnosing and treating cancer using machine learning models to process histological images. The technology involves color deconvolution of tissue images stained with different dyes to identify tumor cells and non-tumor cells, determining a positivity index for medical decision-making, and automatically adjusting patient treatment based on the model's output. This innovative approach aims to enhance cancer diagnosis and treatment through advanced technological applications in the field of oncology. [Extracted from the article]

The patent application titled "Artificial Intelligence (Ai) Based Selective Sequencing Platform Using Oxford Nanopore Technology (Ont)" discusses a novel sequencing technology that combines artificial intelligence and selective sequencing to revolutionize in-vitro diagnosis, pathogen identification, genetic testing, and cancer diagnosis. The technology allows for the selective sequencing of DNA and RNA molecules, enabling the detection of DNA modifications, copy number variations, and single nucleotide polymorphisms. By ejecting unwanted reads during sequencing, the platform reduces costs, shortens diagnosis times, and increases efficiency in identifying pathogens and disease-related genes. The system integrates neural networks and nanopore sequencing signals to provide real-time selective sequencing for various applications, including precision medicine and pathogen detection. [Extracted from the article]

A patent application titled "Plk1 Inhibitor In Combination With Anti-Angiogenics For Treating Metastatic Cancer" was published online, detailing methods for treating metastatic cancer by administering a PLK1 inhibitor and anti-angiogenics to reduce or inhibit cancer progression. The application emphasizes the importance of effective treatments for advanced cancers, such as metastatic cancer, which remains a significant cause of mortality. The inventors propose administering specific inhibitors and therapies to improve therapeutic effects and patient outcomes in treating metastatic cancers, focusing on colorectal cancer as an example. [Extracted from the article]

A patent application titled "Ectonucleotide Pyrophosphatase-Phosphodiesterase-1 (Enpp1) Inhibitors And Uses Thereof" was published online on October 24, 2024, by inventors from various locations. The application focuses on the role of ENPP1 in DNA damage repair, immune responses, and cancer progression. It proposes compounds and methods for inhibiting ENPP1 to treat cancer and other diseases associated with this enzyme. The patent application highlights the potential of ENPP1 inhibitors as a novel therapeutic approach in cancer treatment. [Extracted from the article]

The patent application titled "Methods For Simultaneous Mutation Detection And Methylation Analysis" discusses innovative techniques for identifying rare mutations and epigenetic changes in DNA using molecular barcoding and sequencing technologies. The inventors propose a method that allows for the accurate detection of genetic and epigenetic characteristics from the same DNA sample, enhancing the sensitivity and efficiency of mutation and methylation analysis. This patent application aims to improve clinical management and research in various fields, including cancer, by enabling the simultaneous assessment of genetic and epigenetic alterations in DNA molecules. [Extracted from the article]

Researchers Aksenov, Dorrestein, Melnik, and Quinn have submitted a patent application titled "Bile Acids and Use in Disease Treatment" for approval. The invention focuses on the impact of the microbiome on the chemistry of mammals, specifically examining the effects of bile acid conjugates on various diseases. The pharmaceutical compositions described in the patent aim to modulate levels of bile acid conjugates in subjects with conditions such as inflammatory bowel disease, liver cancer, and diabetes. The patent application provides detailed information on the methods and compositions used to regulate bile acid levels in different bodily regions. [Extracted from the article]

Researchers have submitted a patent application for a method to detect colorectal neoplasms using DNA methylation markers. The application highlights the importance of screening for colorectal cancer due to its prevalence and the potential for early detection through genetic analysis. The technology aims to provide more accurate and user-friendly tools for screening, diagnosis, and monitoring of colorectal cancer using specific DNA markers. The patent application emphasizes the need for high specificity and sensitivity in detecting colorectal neoplasms to improve screening effectiveness and accessibility. [Extracted from the article]

A patent application titled "Antibodies Targeting Immunosuppressive B Cells" was published online by inventors from California, focusing on the development of bispecific or multivalent antibodies to target immunosuppressive B-cell populations in cancer therapy. These binding molecules aim to modulate the anti-tumor immune response and improve treatment outcomes by targeting specific surface markers on immunosuppressive B cells. The patent application highlights the potential of engineered antibody-based therapeutics to enhance treatment efficacy in complex diseases like cancer by altering target-binding affinities and valences. [Extracted from the article]

A patent application has been submitted for methods of assessing lung disease in chest X-rays, aiming to improve early detection of lung cancer through machine learning systems. The application highlights the challenges of late-stage lung cancer diagnosis and the potential benefits of early identification for improved survivability. By utilizing neural networks to analyze chest X-rays, the invention aims to enhance the accuracy of detecting lung nodules, ultimately leading to more effective disease screening and diagnosis. [Extracted from the article]

A patent application by inventor Peter Forsell proposes an artificial stomach to replace the natural stomach in patients who have undergone total gastrectomy due to stomach cancer. The artificial stomach includes features such as a food reservoir, inlet and outlet valves, and a servo reservoir for regulating food intake. This invention aims to improve the quality of life for patients who have had their stomach surgically removed, offering a potential solution to the challenges they face post-surgery. [Extracted from the article]

A patent application titled "Smarca Degraders And Uses Thereof" was published online on October 17, 2024, by inventors from Watertown, MA. The application focuses on compounds that target specific proteins for degradation, particularly SMARCA and PB1 proteins, with potential therapeutic applications in diseases like cancer. The compounds aim to modulate protein degradation pathways and offer new possibilities for disease treatment. The patent application highlights the importance of the Ubiquitin-Proteasome Pathway in regulating protein degradation and its implications for various diseases. [Extracted from the article]

The patent application by Richard Vlasimsky focuses on methods for assessing lung disease, particularly lung cancer, in chest X-rays using machine learning systems. The invention aims to improve early detection of lung nodules through the use of neural networks that analyze X-ray images for abnormalities. By training these systems with data from various sources and utilizing federated learning models, the accuracy of detecting lung nodules in chest X-rays is significantly enhanced. This innovation has the potential to revolutionize disease screening, especially in regions with limited access to CT scanning capabilities, ultimately leading to improved patient outcomes and reduced healthcare costs. [Extracted from the article]

Researchers FUJITA, Kazutaka and HAGIWARA, Koichi have submitted a patent application for a method to prepare samples from lung cancer patients for genetic analysis using next-generation sequencing. The method involves treating biopsy tissues with negative pressure in an isotonic solution to release cells, collecting the solution, and mixing it with cytologic specimens to obtain a cell suspension. By avoiding formalin fixation and paraffin embedding, the method aims to reduce nucleic acid degradation, increase yield, and improve the efficiency of genetic analysis. This innovation could have significant implications for the development of personalized treatment regimens in advanced lung cancer patients. [Extracted from the article]

A patent application titled "Methods Of Treating Brain Cancer" was published online by inventors from Australia. The application highlights the challenges in treating brain tumors, particularly glioblastomas, which are aggressive and deadly. The inventors propose a composition involving 5-fluorouracil, folinic acid, and a cyclodextrin compound for the treatment and prevention of brain and central nervous system cancers, aiming to improve drug delivery and reduce side effects. This development addresses the urgent need for effective chemotherapeutic agents for brain cancer patients, as current treatments have not significantly improved survival rates. [Extracted from the article]

A patent application titled "Controller And Flexible Coils For Administering Therapy, Such As For Cancer Therapy" was published online by inventors from various locations in the United States. The application describes a non-intrusive delivery mechanism for treating diseases like cancer, aiming to provide therapy without the use of drugs by generating electromagnetic or magnetic fields that mimic molecular signals of specific chemicals. The therapy system includes a coil and cable assembly coupled to a controller, allowing patients to receive treatment without visiting a healthcare facility and potentially avoiding traditional side effects associated with cancer treatments. The patent application outlines a portable apparatus and method for generating electromagnetic signals to provide treatment for mammalian ailments, emphasizing the non-invasive and mobile nature of the therapy system. [Extracted from the article]

A patent application titled "Biodosimetry Panels And Methods" was published online by inventors from various locations in the United States. The application aims to provide a biodosimetry assay panel and methods to measure multiple radiation-sensitive protein biomarkers to assess radiation dose and tissue injury, particularly in cases of exposure to ionizing radiation. The invention includes a multiplexed assay kit, a device to measure biomarkers, and methods to assess absorbed radiation dose or tissue injury, offering potential applications in triaging and guiding treatment for individuals exposed to radiation. The patent application emphasizes the need for sensitive and specific biodosimetry tools to identify patients requiring urgent medical attention and improve risk assessment for radiation exposure. [Extracted from the article]